CVS Group (4C9) 주식 개요CVS Group plc는 자회사와 함께 동물병원, 반려동물 화장터, 온라인 약국, 소매업에 종사하고 있습니다. 자세히 보기4C9 펀더멘털 분석스노우플레이크 점수가치 평가3/6미래 성장3/6과거 실적2/6재무 건전성3/6배당3/6강점공정 가치 추정치보다 낮은 32.3% 에서 거래수익은 매년 21.02% 증가할 것으로 예상됩니다.분석가들은 주가가 32.1% 상승할 것이라는 데 동의합니다.위험 분석부채비율이 높네요모든 위험 점검 보기4C9 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€14.003.2% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0867m2016201920222025202620282031Revenue UK£867.4mEarnings UK£20.7mAdvancedSet Fair ValueView all narrativesCVS Group plc 경쟁사RHÖN-KLINIKUMSymbol: XTRA:RHKMarket cap: €836.7mM1 KlinikenSymbol: XTRA:M12Market cap: €352.5mMEDICLINSymbol: XTRA:MEDMarket cap: €179.6mLIMES SchlossklinikenSymbol: XTRA:LIKMarket cap: €147.8m가격 이력 및 성과CVS Group 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가UK£14.0052주 최고가UK£17.4052주 최저가UK£12.60베타1.021개월 변동5.26%3개월 변동-4.76%1년 변동-4.11%3년 변동-42.15%5년 변동-44.49%IPO 이후 변동328.13%최근 뉴스 및 업데이트공시 • May 14Converium Capital Sends Letter to CVS GroupOn May 13, 2026, Converium Capital Inc. announced that it has sent a letter to CVS Group Plc's Board of Directors highlighting the Company's undervaluation and urging the immediate initiation of a £100 million share buyback, equivalent to 12.5% of the Company's current market capitalization. In addition, Converium says a buyback is the highest-return use of capital currently available, the Company has capacity to fund it, and Converium stating that it remains available to discuss, and it is continuing its dialogue with other shareholders in the meantime.공시 • Apr 23Cvs Group plc Announces Appointment of Laura Hagan as Independent Non-Executive Director, Effective May 1, 2026CVS Group plc announced the appointment of Laura Hagan as an Independent Non-Executive Director with effect from May 1, 2026. Laura is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at FeverTree Drinks plc and was, until March 2026, Chief People Officer at Deliveroo plc. Laura's earlier executive roles include Chief People Officer at Gymshark Ltd, Chief HR Officer at Tate & Lyle plc and Group HR Director at Dyson Ltd. Laura has a wealth of experience in people leadership, organisation design optimisation, international expansion and the delivery of customer driven service through technology. Laura's blend of experience operating in both FTSE 250 and fast growth privately owned companies will add value to the board. From the date of her appointment, Laura will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. Laura's appointment, following that of Helen Keays and Jane Bednall announced on March 25, 2026, adds complementary skills and experience to the Board through her extensive listed company experience and her expertise in people development, leadership, customer service and international expansion.공시 • Mar 30+ 1 more updateCVS Group plc Announces Retirement of CEO Richard FairmanCVS Group plc announced that Richard Fairman has informed the Board of his intention to retire from his role as Chief Executive Officer for personal reasons. Richard will remain in post until a successor is appointed, to ensure an orderly transition, and he will continue to drive the business forward in the meantime. Since joining CVS in 2018 as CFO and assuming the role of CEO in 2019, Richard has led the Group through a period of significant strategic progress in support of its purpose to provide the best possible care to animals. Under Richard's leadership, CVS has built a culture centered on clinical excellence, strengthened its position as veterinary employer of choice and delivered sustainable growth alongside successful international expansion into the Australian market. During Richard's tenure, the Group has grown to approximately 9,000 employees including approximately 2,500 vets and 3,300 veterinary nurses and patient care assistants across approximately 475 practices and EBITDA has nearly tripled. Richard also guided the business through to the conclusion of the CMA process and, during the same period, oversaw the Group's step-up to the Main Market of the London Stock Exchange and its subsequent inclusion into the FTSE 250 index.공시 • Mar 25CVS Group plc Announces Board and Committee ChangesCVS Group plc announced the appointment of Helen Keays and Jane Bednall as Independent Non-Executive Directors with effect from 1 April 2026, the retirement of Deborah Kemp with effect from 30 June 2026 and a change in Chair of the Group's Nomination Committee. Deborah Kemp, who joined the board in January 2018 and who is presently Senior Independent Director and Chair of the Remuneration Committee will retire and step down from the Board and all board committees on 30 June 2026. Helen Keays is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at Nichols plc following an executive career in consumer-facing multi-site businesses across retail, mobile telecommunications and retail financial services. Helen has worked at Vodafone plc, latterly as General Manager of Singlepoint, and previously at Sears plc. Helen has previously been an Independent Non-Executive Director of The Restaurant Group, Domino's Pizza UK & Ireland, Communisis plc, Majestic Wine plc, Mattioli Woods plc and Chrysalis Group plc. Helen is an experienced Non-Executive Director and Remuneration Committee Chair and will add value to the board through her expertise in people development, consumer marketing and CRM. From the date of her appointment, Helen Keays will become Chair Designate of the Remuneration Committee and will also become a member of the Group's Audit and Risk Committee and Nomination Committee. Helen will formally become Chair of the Remuneration Committee with effect from 1 July 2026. Jane Bednall is presently an Independent Non-Executive Director of Fuller Smith & Turner plc and Independent Non-Executive Director and Chair of the Remuneration, People and Culture Committee for The Kings Cross Group, appointed on behalf of AustralianSuper, Australia's largest pension fund. This follows an executive career in senior leadership roles at British Airways, InterContinental Hotel Group (IHG), Centrica and most recently SSE plc where she was Chief Marketing Officer and formerly Managing Director of Retail Energy. Jane was previously Non-Executive Director of DFS plc, EI Group plc and Smart Energy GB. Jane will add value to the board through her experience in multi-site retail and leisure businesses and her expertise in branding, consumer behaviour and insights. From the date of her appointment, Jane will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. David Wilton, Chair of CVS, will succeed Richard Gray as Chair of the Nominations Committee with effect from 1 April 2026.공시 • Nov 14+ 1 more updateCVS Group plc to Report First Half, 2026 Results on Feb 26, 2026CVS Group plc announced that they will report first half, 2026 results on Feb 26, 2026공시 • Oct 24CVS Group plc (AIM:CVSG) announces an Equity Buyback for £20 million worth of its shares.CVS Group plc (AIM:CVSG) announces an share repurchase program. Under the program, the company will repurchases up to £20 million. The purpose of the Share Buyback Program is to both return surplus capital to shareholders and reduce the Group's share capital pursuant to its capital allocation policy. As such, all Ordinary Shares repurchased by the Group under the Share Buyback Program will be cancelled. The program will valid till Q1 of calendar year 2026.더 많은 업데이트 보기Recent updates공시 • May 14Converium Capital Sends Letter to CVS GroupOn May 13, 2026, Converium Capital Inc. announced that it has sent a letter to CVS Group Plc's Board of Directors highlighting the Company's undervaluation and urging the immediate initiation of a £100 million share buyback, equivalent to 12.5% of the Company's current market capitalization. In addition, Converium says a buyback is the highest-return use of capital currently available, the Company has capacity to fund it, and Converium stating that it remains available to discuss, and it is continuing its dialogue with other shareholders in the meantime.공시 • Apr 23Cvs Group plc Announces Appointment of Laura Hagan as Independent Non-Executive Director, Effective May 1, 2026CVS Group plc announced the appointment of Laura Hagan as an Independent Non-Executive Director with effect from May 1, 2026. Laura is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at FeverTree Drinks plc and was, until March 2026, Chief People Officer at Deliveroo plc. Laura's earlier executive roles include Chief People Officer at Gymshark Ltd, Chief HR Officer at Tate & Lyle plc and Group HR Director at Dyson Ltd. Laura has a wealth of experience in people leadership, organisation design optimisation, international expansion and the delivery of customer driven service through technology. Laura's blend of experience operating in both FTSE 250 and fast growth privately owned companies will add value to the board. From the date of her appointment, Laura will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. Laura's appointment, following that of Helen Keays and Jane Bednall announced on March 25, 2026, adds complementary skills and experience to the Board through her extensive listed company experience and her expertise in people development, leadership, customer service and international expansion.공시 • Mar 30+ 1 more updateCVS Group plc Announces Retirement of CEO Richard FairmanCVS Group plc announced that Richard Fairman has informed the Board of his intention to retire from his role as Chief Executive Officer for personal reasons. Richard will remain in post until a successor is appointed, to ensure an orderly transition, and he will continue to drive the business forward in the meantime. Since joining CVS in 2018 as CFO and assuming the role of CEO in 2019, Richard has led the Group through a period of significant strategic progress in support of its purpose to provide the best possible care to animals. Under Richard's leadership, CVS has built a culture centered on clinical excellence, strengthened its position as veterinary employer of choice and delivered sustainable growth alongside successful international expansion into the Australian market. During Richard's tenure, the Group has grown to approximately 9,000 employees including approximately 2,500 vets and 3,300 veterinary nurses and patient care assistants across approximately 475 practices and EBITDA has nearly tripled. Richard also guided the business through to the conclusion of the CMA process and, during the same period, oversaw the Group's step-up to the Main Market of the London Stock Exchange and its subsequent inclusion into the FTSE 250 index.공시 • Mar 25CVS Group plc Announces Board and Committee ChangesCVS Group plc announced the appointment of Helen Keays and Jane Bednall as Independent Non-Executive Directors with effect from 1 April 2026, the retirement of Deborah Kemp with effect from 30 June 2026 and a change in Chair of the Group's Nomination Committee. Deborah Kemp, who joined the board in January 2018 and who is presently Senior Independent Director and Chair of the Remuneration Committee will retire and step down from the Board and all board committees on 30 June 2026. Helen Keays is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at Nichols plc following an executive career in consumer-facing multi-site businesses across retail, mobile telecommunications and retail financial services. Helen has worked at Vodafone plc, latterly as General Manager of Singlepoint, and previously at Sears plc. Helen has previously been an Independent Non-Executive Director of The Restaurant Group, Domino's Pizza UK & Ireland, Communisis plc, Majestic Wine plc, Mattioli Woods plc and Chrysalis Group plc. Helen is an experienced Non-Executive Director and Remuneration Committee Chair and will add value to the board through her expertise in people development, consumer marketing and CRM. From the date of her appointment, Helen Keays will become Chair Designate of the Remuneration Committee and will also become a member of the Group's Audit and Risk Committee and Nomination Committee. Helen will formally become Chair of the Remuneration Committee with effect from 1 July 2026. Jane Bednall is presently an Independent Non-Executive Director of Fuller Smith & Turner plc and Independent Non-Executive Director and Chair of the Remuneration, People and Culture Committee for The Kings Cross Group, appointed on behalf of AustralianSuper, Australia's largest pension fund. This follows an executive career in senior leadership roles at British Airways, InterContinental Hotel Group (IHG), Centrica and most recently SSE plc where she was Chief Marketing Officer and formerly Managing Director of Retail Energy. Jane was previously Non-Executive Director of DFS plc, EI Group plc and Smart Energy GB. Jane will add value to the board through her experience in multi-site retail and leisure businesses and her expertise in branding, consumer behaviour and insights. From the date of her appointment, Jane will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. David Wilton, Chair of CVS, will succeed Richard Gray as Chair of the Nominations Committee with effect from 1 April 2026.공시 • Nov 14+ 1 more updateCVS Group plc to Report First Half, 2026 Results on Feb 26, 2026CVS Group plc announced that they will report first half, 2026 results on Feb 26, 2026공시 • Oct 24CVS Group plc (AIM:CVSG) announces an Equity Buyback for £20 million worth of its shares.CVS Group plc (AIM:CVSG) announces an share repurchase program. Under the program, the company will repurchases up to £20 million. The purpose of the Share Buyback Program is to both return surplus capital to shareholders and reduce the Group's share capital pursuant to its capital allocation policy. As such, all Ordinary Shares repurchased by the Group under the Share Buyback Program will be cancelled. The program will valid till Q1 of calendar year 2026.공시 • Oct 08+ 1 more updateCVS Group plc Recommends Final Dividend for the Year 2025, Payable on 5 December 2025The Board of CVS Group plc recommends the payment of a final dividend of 8.5p per Ordinary share (2024: 8.0p), subject to shareholder approval at the Annual General Meeting to be held on 18 November 2025. The ex-dividend date is 6 November 2025, the record date is 7 November 2025 and the dividend payment date is 5 December 2025.공시 • May 20Anima Care UK Limited acquired Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million.Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services. For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million. The expected completion date of the transaction is within the next five weeks. Anima Care UK Limited completed the acquisition of Crematoria operations of CVS Group plc (AIM:CVSG) on May 19, 2025. In related transaction, CVS Group plc completed the acquisition of VPP Group. Christopher Golden, James Steel and Andrew Clark of Peel Hunt LLP acted as financial advisor for CVS Group plc. Toby Flaux, Michael Burke, James Thompson and Milo Bonser brokered the transaction.공시 • Apr 25Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million.Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services. For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million. The expected completion date of the transaction is within the next five weeks.공시 • Nov 20CVS Group plc Proposes Final Dividend, Payable on 29 November 2024Subject to shareholder approval at the AGM, CVS Group plc intends to pay its previously announced final dividend of 8.0 pence per ordinary share on 29 November 2024 to holders on the register as at 1 November 2024. The ex-dividend date was 31 October 2024.공시 • Nov 16+ 1 more updateCVS Group plc to Report Fiscal Year 2025 Results on Sep 25, 2025CVS Group plc announced that they will report fiscal year 2025 results on Sep 25, 2025Upcoming Dividend • Oct 24Upcoming dividend of UK£0.08 per shareEligible shareholders must have bought the stock before 31 October 2024. Payment date: 29 November 2024. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (2.9%).Declared Dividend • Sep 29Dividend of UK£0.08 announcedShareholders will receive a dividend of UK£0.08. Ex-date: 31st October 2024 Payment date: 29th November 2024 Dividend yield will be 0.6%, which is lower than the industry average of 3.3%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 67% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Sep 26Full year 2024 earnings released: EPS: UK£0.36 (vs UK£0.59 in FY 2023)Full year 2024 results: EPS: UK£0.36 (down from UK£0.59 in FY 2023). Revenue: UK£647.3m (up 6.4% from FY 2023). Net income: UK£26.2m (down 38% from FY 2023). Profit margin: 4.0% (down from 6.9% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Jun 30Independent Non-Executive Chairman recently bought €3.1m worth of stockOn the 25th of June, David Wilton bought around 3k shares on-market at roughly €1,246 per share. This transaction amounted to 38% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was David's only on-market trade for the last 12 months.공시 • Jun 19CVS Group plc Announces Resignation of Ben Jacklin as Executive DirectorCVS Group plc announces that Ben Jacklin, Executive Director, has resigned. Ben's managerial and operational responsibilities, including the provision of clinical guidance to the Board, have been assumed by other senior members of the Group.Board Change • May 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non Executive Director Joanne Shaw was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • May 01CVS Group plc Announces Board ChangesCVS Group plc announced the appointment of David Wilton as Chair with effect from 1 May 2024. David has served as an Independent Non-executive Director of the Company since September 2021. David is a qualified Chartered Accountant with more than 30 years' post-qualification experience as a Chief Financial Officer, Non-Executive Director (NED), Chair and consultant after many years in corporate finance, primarily in mid-cap M&A with Rothschilds. David has held roles in both public and private-equity backed companies including as CFO of Sumo Group plc, Group Finance Director of WYG plc and NED and Chair of the Audit Committee of Sweett Group plc. David was NED and subsequently Chair at Frontier Developments plc until November 2023. David is currently also NED and Chair Designate at Gateley (Holdings) plc. He has extensive experience of people businesses and of regulatory processes. David also brings to the Chair role a significant amount of technical expertise, which will support CVS in its strategic delivery of investment in technology. David Wilton's appointment follows a comprehensive search by the Nomination Committee, supported by a blue chip recruitment firm who sourced a number of high quality candidates. The Board would like to thank Deborah Kemp, the Group's Senior Independent Director who has been acting as Interim Chair during the search period. David will remain as Audit Committee Chair until this process is completed, at which point he will then step down as a member of the Audit Committee.Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €13.40, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 13x in the Healthcare industry in Germany. Total loss to shareholders of 37% over the past three years.Reported Earnings • Mar 04First half 2024 earnings released: EPS: UK£0.20 (vs UK£0.30 in 1H 2023)First half 2024 results: EPS: UK£0.20 (down from UK£0.30 in 1H 2023). Revenue: UK£329.9m (up 11% from 1H 2023). Net income: UK£14.6m (down 31% from 1H 2023). Profit margin: 4.4% (down from 7.1% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.공시 • Dec 13+ 2 more updatesCVS Group plc to Report First Half, 2024 Results on Feb 29, 2024CVS Group plc announced that they will report first half, 2024 results on Feb 29, 2024공시 • Oct 27CVS Announce Director ChangesCVS announced that its Chair Richard Connell has taken the difficult decision to resign with immediate effect due to ill health. Deborah Kemp, the Group's Senior Independent Director will assume the role of Chair for the interim period whilst the Board commences a process to appoint a permanent successor.Upcoming Dividend • Oct 26Upcoming dividend of UK£0.075 per share at 0.5% yieldEligible shareholders must have bought the stock before 02 November 2023. Payment date: 08 December 2023. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (3.5%).Reported Earnings • Sep 21Full year 2023 earnings released: EPS: UK£0.59 (vs UK£0.36 in FY 2022)Full year 2023 results: EPS: UK£0.59 (up from UK£0.36 in FY 2022). Revenue: UK£608.3m (up 9.8% from FY 2022). Net income: UK£41.9m (up 63% from FY 2022). Profit margin: 6.9% (up from 4.6% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.공시 • Sep 21CVS Group plc Recommends Final Dividend, Payable on 8 December 2023CVS Group plc recommends continuation of progressive dividend policy, with the payment of a final dividend of 7.5 pence per Ordinary share (2022: 7.0 pence). The ex-dividend date is 2 November 2023 and the dividend payment date is 8 December 2023.Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €19.70, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 18x in the Healthcare industry in Germany. Total returns to shareholders of 57% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €28.55 per share.Buying Opportunity • Sep 07Now 26% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be €26.90, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 42%. For the next 3 years, revenue is forecast to grow by 6.5% per annum. Earnings is also forecast to grow by 19% per annum over the same time period.Reported Earnings • Feb 26First half 2023 earnings released: EPS: UK£0.30 (vs UK£0.25 in 1H 2022)First half 2023 results: EPS: UK£0.30 (up from UK£0.25 in 1H 2022). Revenue: UK£296.3m (up 8.3% from 1H 2022). Net income: UK£21.1m (up 21% from 1H 2022). Profit margin: 7.1% (up from 6.4% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.공시 • Nov 23CVS Group plc Recommends Dividend, Payable on 2 December 2022CVS Group plc announced that as previously announced, and subject to shareholder approval at the AGM, the company intends to pay a dividend of 7.0 pence per ordinary share on 2 December 2022 to holders on the register as at 18 November 2022. The ex-dividend date for this timetable is 17 November 2022.공시 • Nov 12+ 2 more updatesCVS Group plc to Report Q4, 2023 Results on Sep 21, 2023CVS Group plc announced that they will report Q4, 2023 results on Sep 21, 2023Buying Opportunity • Nov 11Now 21% undervaluedOver the last 90 days, the stock is up 2.9%. The fair value is estimated to be €27.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 43%. For the next 3 years, revenue is forecast to grow by 5.7% per annum. Earnings is also forecast to grow by 18% per annum over the same time period.Upcoming Dividend • Nov 10Upcoming dividend of UK£0.07 per shareEligible shareholders must have bought the stock before 17 November 2022. Payment date: 02 December 2022. Payout ratio is a comfortable 19% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (4.1%).Recent Insider Transactions • Sep 29Independent Non-Executive Chairman recently bought €83k worth of stockOn the 22nd of September, Richard Connell bought around 5k shares on-market at roughly €18.56 per share. This transaction amounted to 2.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of €256k worth in shares.Reported Earnings • Sep 23Full year 2022 earnings released: EPS: UK£0.36 (vs UK£0.27 in FY 2021)Full year 2022 results: EPS: UK£0.36 (up from UK£0.27 in FY 2021). Revenue: UK£554.2m (up 8.6% from FY 2021). Net income: UK£25.7m (up 33% from FY 2021). Profit margin: 4.6% (up from 3.8% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.공시 • Sep 22+ 1 more updateCVS Group plc Recommending Final DividendCVS Group plc the board is recommending a continuation of progressive dividend policy, with the payment of a final dividend of 7.0 pence per Ordinary share (2021: 6.5 pence).공시 • Jul 02CVS Group plc (AIM:CVSG) acquired Ocvc Limited for £ 3 million.CVS Group plc (AIM:CVSG) acquired Ocvc Limited for £ 3 million on June 10, 2022. The consideration was funded from the Group's cash balances. Aubrey Powell, Jen Boorer, and Rachel Hayes of Singer Capital Markets Securities Limited acted as financial advisor to CVS Group plc. CVS Group plc (AIM:CVSG) completed the acquisition of Ocvc Limited on June 10, 2022.공시 • May 08CVS Group plc (AIM:CVSG) acquired Anton Vets Ltd for £6 million.CVS Group plc (AIM:CVSG) acquired Anton Vets Ltd for £6 million on May 5, 2022. The consideration is being funded using the CVS Group's existing bank facilities. Aubrey Powell, Jen Boorer and Rachel Hayes of Singer Capital Markets Securities Limited acted as financial advisor to CVS Group plc. CVS Group plc (AIM:CVSG) completed the acquisition of Anton Vets Ltd on May 5, 2022.Valuation Update With 7 Day Price Move • Feb 23Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €18.75, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 16x in the Healthcare industry in Germany. Total returns to shareholders of 260% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €34.78 per share.Recent Insider Transactions • Dec 09Independent Non-Executive Chairman recently bought €63k worth of stockOn the 6th of December, Richard Connell bought around 3k shares on-market at roughly €25.13 per share. In the last 3 months, they made an even bigger purchase worth €110k. Richard has been a buyer over the last 12 months, purchasing a net total of €278k worth in shares.Recent Insider Transactions • Nov 27Independent Non-Executive Chairman recently bought €110k worth of stockOn the 25th of November, Richard Connell bought around 4k shares on-market at roughly €26.17 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of €216k worth in shares.Upcoming Dividend • Nov 11Upcoming dividend of UK£0.065 per shareEligible shareholders must have bought the stock before 18 November 2021. Payment date: 03 December 2021. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (2.4%).Board Change • Nov 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Senior Independent Non-Executive Director Deborah Kemp was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Senior Independent Non-Executive Director Deborah Kemp was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Executive Departure • Oct 01Senior Independent Non-Executive Director Michael McCollum has left the companyOn the 23rd of September, Michael McCollum's tenure as Senior Independent Non-Executive Director ended. As of June 2021, Michael still personally held 38.68k shares (€1.1m worth at the time). Michael is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.83 years, which is considered inexperienced in the Simply Wall St Risk Model.Reported Earnings • Sep 24Full year 2021 earnings released: EPS UK£0.27 (vs UK£0.081 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£510.1m (up 19% from FY 2020). Net income: UK£19.3m (up 239% from FY 2020). Profit margin: 3.8% (up from 1.3% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.Executive Departure • Sep 24Senior Independent Non-Executive Director Michael McCollum has left the companyOn the 23rd of September, Michael McCollum's tenure as Senior Independent Non-Executive Director ended after 8.5 years in the role. As of June 2021, Michael still personally held 38.68k shares (€1.1m worth at the time). Michael is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.83 years, which is considered inexperienced in the Simply Wall St Risk Model.공시 • May 01CVS Group plc Provides Group Earnings Guidance for the Full Year Ending June 30, 2021CVS Group plc provided earnings guidance for the full year ending June 30, 2021. This, coupled with the continued delivery of the vaccination programme and further easing of lockdown restrictions, means the Board is increasingly confident that this strong performance will continue for the remaining months of this financial year. Consequently, the Group now expects full year revenue to be ahead of current management expectations.Recent Insider Transactions • Mar 31Non-Executive Director recently bought €66k worth of stockOn the 29th of March, Richard Gray bought around 3k shares on-market at roughly €21.93 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Mar 26First half 2021 earnings released: EPS UK£0.16 (vs UK£0.079 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£245.6m (up 9.4% from 1H 2020). Net income: UK£11.3m (up 102% from 1H 2020). Profit margin: 4.6% (up from 2.5% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Mar 11New 90-day high: €20.62The company is up 37% from its price of €15.06 on 10 December 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €25.14 per share.공시 • Jan 28+ 2 more updatesCVS Group plc, Annual General Meeting, Nov 24, 2021CVS Group plc, Annual General Meeting, Nov 24, 2021.Is New 90 Day High Low • Jan 22New 90-day high: €17.06The company is up 25% from its price of €13.67 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.26 per share.Is New 90 Day High Low • Jan 05New 90-day high: €16.96The company is up 29% from its price of €13.18 on 07 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.75 per share.Is New 90 Day High Low • Dec 18New 90-day high: €16.49The company is up 32% from its price of €12.53 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.87 per share.공시 • Nov 26CVS Group plc Announces Appointment of Enrico Tizzano as its First Chief Technology OfficerCVS Group plc announced that the Group has strengthened its management team with the appointment of Enrico Tizzano as its first Chief Technology Officer. Enrico will support the effective use of technology and data in delivery of the Group's strategic objectives and has a wealth of experience from previous CTO roles in large, consumer-facing organizations.Is New 90 Day High Low • Nov 05New 90-day high: €14.38The company is up 14% from its price of €12.57 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.11 per share.Is New 90 Day High Low • Sep 28New 90-day high: €13.89The company is up 26% from its price of €11.06 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.81 per share.Reported Earnings • Sep 26Full year earnings released - EPS €0.081Over the last 12 months the company has reported total profits of UK£5.70m, down 31% from the prior year. Total revenue was UK£427.8m over the last 12 months, up 5.2% from the prior year. Profit margins were 1.3%, which is in line with last year.공시 • Sep 24CVS Group plc Not Propose Final DividendThe directors of CVS Group plc have proposed a final dividend of £nil (2019: 5.5 pence) per share, giving a total of £nil (2019: £3.9 million). During the year a dividend of 5.5 pence per share amounting to £3.9 million was paid (2019: £3.5 million).주주 수익률4C9DE HealthcareDE 시장7D2.9%-6.3%1.6%1Y-4.1%-16.5%2.2%전체 주주 수익률 보기수익률 대 산업: 4C9은 지난 1년 동안 -16.5%의 수익을 기록한 German Healthcare 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: 4C9은 지난 1년 동안 2.2%를 기록한 German 시장보다 저조한 성과를 냈습니다.주가 변동성Is 4C9's price volatile compared to industry and market?4C9 volatility4C9 Average Weekly Movement5.4%Healthcare Industry Average Movement6.5%Market Average Movement6.0%10% most volatile stocks in DE Market12.3%10% least volatile stocks in DE Market2.7%안정적인 주가: 4C9는 지난 3개월 동안 German 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: 4C9의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트19999,000Richard William Fairmanwww.cvsukltd.co.ukCVS Group plc는 자회사와 함께 동물병원, 반려동물 화장터, 온라인 약국 및 소매 사업을 영위하고 있습니다. 이 회사는 수의학 진료, 실험실, 화장터 및 온라인 소매 사업 부문을 통해 운영됩니다. 동물 수의학 진료 및 보완 수의학 진단 사업을 운영합니다.더 보기CVS Group plc 기초 지표 요약CVS Group의 순이익과 매출은 시가총액과 어떻게 비교됩니까?4C9 기초 통계시가총액€1.00b순이익 (TTM)€19.03m매출 (TTM)€798.86m52.8x주가수익비율(P/E)1.3x주가매출비율(P/S)4C9는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표4C9 손익계산서 (TTM)매출UK£692.80m매출원가UK£393.20m총이익UK£299.60m기타 비용UK£283.10m순이익UK£16.50m최근 보고된 실적Dec 31, 2025다음 실적 발표일Sep 24, 2026주당순이익(EPS)0.24총이익률43.24%순이익률2.38%부채/자본 비율56.9%4C9의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당0.7%현재 배당 수익률37%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/28 19:06종가2026/05/28 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스CVS Group plc는 13명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Sharanya GajapathyBarclaysJames BaylissBerenbergAllan SmylieDavy10명의 분석가 더 보기
공시 • May 14Converium Capital Sends Letter to CVS GroupOn May 13, 2026, Converium Capital Inc. announced that it has sent a letter to CVS Group Plc's Board of Directors highlighting the Company's undervaluation and urging the immediate initiation of a £100 million share buyback, equivalent to 12.5% of the Company's current market capitalization. In addition, Converium says a buyback is the highest-return use of capital currently available, the Company has capacity to fund it, and Converium stating that it remains available to discuss, and it is continuing its dialogue with other shareholders in the meantime.
공시 • Apr 23Cvs Group plc Announces Appointment of Laura Hagan as Independent Non-Executive Director, Effective May 1, 2026CVS Group plc announced the appointment of Laura Hagan as an Independent Non-Executive Director with effect from May 1, 2026. Laura is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at FeverTree Drinks plc and was, until March 2026, Chief People Officer at Deliveroo plc. Laura's earlier executive roles include Chief People Officer at Gymshark Ltd, Chief HR Officer at Tate & Lyle plc and Group HR Director at Dyson Ltd. Laura has a wealth of experience in people leadership, organisation design optimisation, international expansion and the delivery of customer driven service through technology. Laura's blend of experience operating in both FTSE 250 and fast growth privately owned companies will add value to the board. From the date of her appointment, Laura will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. Laura's appointment, following that of Helen Keays and Jane Bednall announced on March 25, 2026, adds complementary skills and experience to the Board through her extensive listed company experience and her expertise in people development, leadership, customer service and international expansion.
공시 • Mar 30+ 1 more updateCVS Group plc Announces Retirement of CEO Richard FairmanCVS Group plc announced that Richard Fairman has informed the Board of his intention to retire from his role as Chief Executive Officer for personal reasons. Richard will remain in post until a successor is appointed, to ensure an orderly transition, and he will continue to drive the business forward in the meantime. Since joining CVS in 2018 as CFO and assuming the role of CEO in 2019, Richard has led the Group through a period of significant strategic progress in support of its purpose to provide the best possible care to animals. Under Richard's leadership, CVS has built a culture centered on clinical excellence, strengthened its position as veterinary employer of choice and delivered sustainable growth alongside successful international expansion into the Australian market. During Richard's tenure, the Group has grown to approximately 9,000 employees including approximately 2,500 vets and 3,300 veterinary nurses and patient care assistants across approximately 475 practices and EBITDA has nearly tripled. Richard also guided the business through to the conclusion of the CMA process and, during the same period, oversaw the Group's step-up to the Main Market of the London Stock Exchange and its subsequent inclusion into the FTSE 250 index.
공시 • Mar 25CVS Group plc Announces Board and Committee ChangesCVS Group plc announced the appointment of Helen Keays and Jane Bednall as Independent Non-Executive Directors with effect from 1 April 2026, the retirement of Deborah Kemp with effect from 30 June 2026 and a change in Chair of the Group's Nomination Committee. Deborah Kemp, who joined the board in January 2018 and who is presently Senior Independent Director and Chair of the Remuneration Committee will retire and step down from the Board and all board committees on 30 June 2026. Helen Keays is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at Nichols plc following an executive career in consumer-facing multi-site businesses across retail, mobile telecommunications and retail financial services. Helen has worked at Vodafone plc, latterly as General Manager of Singlepoint, and previously at Sears plc. Helen has previously been an Independent Non-Executive Director of The Restaurant Group, Domino's Pizza UK & Ireland, Communisis plc, Majestic Wine plc, Mattioli Woods plc and Chrysalis Group plc. Helen is an experienced Non-Executive Director and Remuneration Committee Chair and will add value to the board through her expertise in people development, consumer marketing and CRM. From the date of her appointment, Helen Keays will become Chair Designate of the Remuneration Committee and will also become a member of the Group's Audit and Risk Committee and Nomination Committee. Helen will formally become Chair of the Remuneration Committee with effect from 1 July 2026. Jane Bednall is presently an Independent Non-Executive Director of Fuller Smith & Turner plc and Independent Non-Executive Director and Chair of the Remuneration, People and Culture Committee for The Kings Cross Group, appointed on behalf of AustralianSuper, Australia's largest pension fund. This follows an executive career in senior leadership roles at British Airways, InterContinental Hotel Group (IHG), Centrica and most recently SSE plc where she was Chief Marketing Officer and formerly Managing Director of Retail Energy. Jane was previously Non-Executive Director of DFS plc, EI Group plc and Smart Energy GB. Jane will add value to the board through her experience in multi-site retail and leisure businesses and her expertise in branding, consumer behaviour and insights. From the date of her appointment, Jane will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. David Wilton, Chair of CVS, will succeed Richard Gray as Chair of the Nominations Committee with effect from 1 April 2026.
공시 • Nov 14+ 1 more updateCVS Group plc to Report First Half, 2026 Results on Feb 26, 2026CVS Group plc announced that they will report first half, 2026 results on Feb 26, 2026
공시 • Oct 24CVS Group plc (AIM:CVSG) announces an Equity Buyback for £20 million worth of its shares.CVS Group plc (AIM:CVSG) announces an share repurchase program. Under the program, the company will repurchases up to £20 million. The purpose of the Share Buyback Program is to both return surplus capital to shareholders and reduce the Group's share capital pursuant to its capital allocation policy. As such, all Ordinary Shares repurchased by the Group under the Share Buyback Program will be cancelled. The program will valid till Q1 of calendar year 2026.
공시 • May 14Converium Capital Sends Letter to CVS GroupOn May 13, 2026, Converium Capital Inc. announced that it has sent a letter to CVS Group Plc's Board of Directors highlighting the Company's undervaluation and urging the immediate initiation of a £100 million share buyback, equivalent to 12.5% of the Company's current market capitalization. In addition, Converium says a buyback is the highest-return use of capital currently available, the Company has capacity to fund it, and Converium stating that it remains available to discuss, and it is continuing its dialogue with other shareholders in the meantime.
공시 • Apr 23Cvs Group plc Announces Appointment of Laura Hagan as Independent Non-Executive Director, Effective May 1, 2026CVS Group plc announced the appointment of Laura Hagan as an Independent Non-Executive Director with effect from May 1, 2026. Laura is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at FeverTree Drinks plc and was, until March 2026, Chief People Officer at Deliveroo plc. Laura's earlier executive roles include Chief People Officer at Gymshark Ltd, Chief HR Officer at Tate & Lyle plc and Group HR Director at Dyson Ltd. Laura has a wealth of experience in people leadership, organisation design optimisation, international expansion and the delivery of customer driven service through technology. Laura's blend of experience operating in both FTSE 250 and fast growth privately owned companies will add value to the board. From the date of her appointment, Laura will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. Laura's appointment, following that of Helen Keays and Jane Bednall announced on March 25, 2026, adds complementary skills and experience to the Board through her extensive listed company experience and her expertise in people development, leadership, customer service and international expansion.
공시 • Mar 30+ 1 more updateCVS Group plc Announces Retirement of CEO Richard FairmanCVS Group plc announced that Richard Fairman has informed the Board of his intention to retire from his role as Chief Executive Officer for personal reasons. Richard will remain in post until a successor is appointed, to ensure an orderly transition, and he will continue to drive the business forward in the meantime. Since joining CVS in 2018 as CFO and assuming the role of CEO in 2019, Richard has led the Group through a period of significant strategic progress in support of its purpose to provide the best possible care to animals. Under Richard's leadership, CVS has built a culture centered on clinical excellence, strengthened its position as veterinary employer of choice and delivered sustainable growth alongside successful international expansion into the Australian market. During Richard's tenure, the Group has grown to approximately 9,000 employees including approximately 2,500 vets and 3,300 veterinary nurses and patient care assistants across approximately 475 practices and EBITDA has nearly tripled. Richard also guided the business through to the conclusion of the CMA process and, during the same period, oversaw the Group's step-up to the Main Market of the London Stock Exchange and its subsequent inclusion into the FTSE 250 index.
공시 • Mar 25CVS Group plc Announces Board and Committee ChangesCVS Group plc announced the appointment of Helen Keays and Jane Bednall as Independent Non-Executive Directors with effect from 1 April 2026, the retirement of Deborah Kemp with effect from 30 June 2026 and a change in Chair of the Group's Nomination Committee. Deborah Kemp, who joined the board in January 2018 and who is presently Senior Independent Director and Chair of the Remuneration Committee will retire and step down from the Board and all board committees on 30 June 2026. Helen Keays is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at Nichols plc following an executive career in consumer-facing multi-site businesses across retail, mobile telecommunications and retail financial services. Helen has worked at Vodafone plc, latterly as General Manager of Singlepoint, and previously at Sears plc. Helen has previously been an Independent Non-Executive Director of The Restaurant Group, Domino's Pizza UK & Ireland, Communisis plc, Majestic Wine plc, Mattioli Woods plc and Chrysalis Group plc. Helen is an experienced Non-Executive Director and Remuneration Committee Chair and will add value to the board through her expertise in people development, consumer marketing and CRM. From the date of her appointment, Helen Keays will become Chair Designate of the Remuneration Committee and will also become a member of the Group's Audit and Risk Committee and Nomination Committee. Helen will formally become Chair of the Remuneration Committee with effect from 1 July 2026. Jane Bednall is presently an Independent Non-Executive Director of Fuller Smith & Turner plc and Independent Non-Executive Director and Chair of the Remuneration, People and Culture Committee for The Kings Cross Group, appointed on behalf of AustralianSuper, Australia's largest pension fund. This follows an executive career in senior leadership roles at British Airways, InterContinental Hotel Group (IHG), Centrica and most recently SSE plc where she was Chief Marketing Officer and formerly Managing Director of Retail Energy. Jane was previously Non-Executive Director of DFS plc, EI Group plc and Smart Energy GB. Jane will add value to the board through her experience in multi-site retail and leisure businesses and her expertise in branding, consumer behaviour and insights. From the date of her appointment, Jane will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. David Wilton, Chair of CVS, will succeed Richard Gray as Chair of the Nominations Committee with effect from 1 April 2026.
공시 • Nov 14+ 1 more updateCVS Group plc to Report First Half, 2026 Results on Feb 26, 2026CVS Group plc announced that they will report first half, 2026 results on Feb 26, 2026
공시 • Oct 24CVS Group plc (AIM:CVSG) announces an Equity Buyback for £20 million worth of its shares.CVS Group plc (AIM:CVSG) announces an share repurchase program. Under the program, the company will repurchases up to £20 million. The purpose of the Share Buyback Program is to both return surplus capital to shareholders and reduce the Group's share capital pursuant to its capital allocation policy. As such, all Ordinary Shares repurchased by the Group under the Share Buyback Program will be cancelled. The program will valid till Q1 of calendar year 2026.
공시 • Oct 08+ 1 more updateCVS Group plc Recommends Final Dividend for the Year 2025, Payable on 5 December 2025The Board of CVS Group plc recommends the payment of a final dividend of 8.5p per Ordinary share (2024: 8.0p), subject to shareholder approval at the Annual General Meeting to be held on 18 November 2025. The ex-dividend date is 6 November 2025, the record date is 7 November 2025 and the dividend payment date is 5 December 2025.
공시 • May 20Anima Care UK Limited acquired Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million.Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services. For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million. The expected completion date of the transaction is within the next five weeks. Anima Care UK Limited completed the acquisition of Crematoria operations of CVS Group plc (AIM:CVSG) on May 19, 2025. In related transaction, CVS Group plc completed the acquisition of VPP Group. Christopher Golden, James Steel and Andrew Clark of Peel Hunt LLP acted as financial advisor for CVS Group plc. Toby Flaux, Michael Burke, James Thompson and Milo Bonser brokered the transaction.
공시 • Apr 25Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million.Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services. For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million. The expected completion date of the transaction is within the next five weeks.
공시 • Nov 20CVS Group plc Proposes Final Dividend, Payable on 29 November 2024Subject to shareholder approval at the AGM, CVS Group plc intends to pay its previously announced final dividend of 8.0 pence per ordinary share on 29 November 2024 to holders on the register as at 1 November 2024. The ex-dividend date was 31 October 2024.
공시 • Nov 16+ 1 more updateCVS Group plc to Report Fiscal Year 2025 Results on Sep 25, 2025CVS Group plc announced that they will report fiscal year 2025 results on Sep 25, 2025
Upcoming Dividend • Oct 24Upcoming dividend of UK£0.08 per shareEligible shareholders must have bought the stock before 31 October 2024. Payment date: 29 November 2024. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (2.9%).
Declared Dividend • Sep 29Dividend of UK£0.08 announcedShareholders will receive a dividend of UK£0.08. Ex-date: 31st October 2024 Payment date: 29th November 2024 Dividend yield will be 0.6%, which is lower than the industry average of 3.3%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 67% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Sep 26Full year 2024 earnings released: EPS: UK£0.36 (vs UK£0.59 in FY 2023)Full year 2024 results: EPS: UK£0.36 (down from UK£0.59 in FY 2023). Revenue: UK£647.3m (up 6.4% from FY 2023). Net income: UK£26.2m (down 38% from FY 2023). Profit margin: 4.0% (down from 6.9% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Jun 30Independent Non-Executive Chairman recently bought €3.1m worth of stockOn the 25th of June, David Wilton bought around 3k shares on-market at roughly €1,246 per share. This transaction amounted to 38% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was David's only on-market trade for the last 12 months.
공시 • Jun 19CVS Group plc Announces Resignation of Ben Jacklin as Executive DirectorCVS Group plc announces that Ben Jacklin, Executive Director, has resigned. Ben's managerial and operational responsibilities, including the provision of clinical guidance to the Board, have been assumed by other senior members of the Group.
Board Change • May 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non Executive Director Joanne Shaw was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • May 01CVS Group plc Announces Board ChangesCVS Group plc announced the appointment of David Wilton as Chair with effect from 1 May 2024. David has served as an Independent Non-executive Director of the Company since September 2021. David is a qualified Chartered Accountant with more than 30 years' post-qualification experience as a Chief Financial Officer, Non-Executive Director (NED), Chair and consultant after many years in corporate finance, primarily in mid-cap M&A with Rothschilds. David has held roles in both public and private-equity backed companies including as CFO of Sumo Group plc, Group Finance Director of WYG plc and NED and Chair of the Audit Committee of Sweett Group plc. David was NED and subsequently Chair at Frontier Developments plc until November 2023. David is currently also NED and Chair Designate at Gateley (Holdings) plc. He has extensive experience of people businesses and of regulatory processes. David also brings to the Chair role a significant amount of technical expertise, which will support CVS in its strategic delivery of investment in technology. David Wilton's appointment follows a comprehensive search by the Nomination Committee, supported by a blue chip recruitment firm who sourced a number of high quality candidates. The Board would like to thank Deborah Kemp, the Group's Senior Independent Director who has been acting as Interim Chair during the search period. David will remain as Audit Committee Chair until this process is completed, at which point he will then step down as a member of the Audit Committee.
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €13.40, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 13x in the Healthcare industry in Germany. Total loss to shareholders of 37% over the past three years.
Reported Earnings • Mar 04First half 2024 earnings released: EPS: UK£0.20 (vs UK£0.30 in 1H 2023)First half 2024 results: EPS: UK£0.20 (down from UK£0.30 in 1H 2023). Revenue: UK£329.9m (up 11% from 1H 2023). Net income: UK£14.6m (down 31% from 1H 2023). Profit margin: 4.4% (down from 7.1% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
공시 • Dec 13+ 2 more updatesCVS Group plc to Report First Half, 2024 Results on Feb 29, 2024CVS Group plc announced that they will report first half, 2024 results on Feb 29, 2024
공시 • Oct 27CVS Announce Director ChangesCVS announced that its Chair Richard Connell has taken the difficult decision to resign with immediate effect due to ill health. Deborah Kemp, the Group's Senior Independent Director will assume the role of Chair for the interim period whilst the Board commences a process to appoint a permanent successor.
Upcoming Dividend • Oct 26Upcoming dividend of UK£0.075 per share at 0.5% yieldEligible shareholders must have bought the stock before 02 November 2023. Payment date: 08 December 2023. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (3.5%).
Reported Earnings • Sep 21Full year 2023 earnings released: EPS: UK£0.59 (vs UK£0.36 in FY 2022)Full year 2023 results: EPS: UK£0.59 (up from UK£0.36 in FY 2022). Revenue: UK£608.3m (up 9.8% from FY 2022). Net income: UK£41.9m (up 63% from FY 2022). Profit margin: 6.9% (up from 4.6% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
공시 • Sep 21CVS Group plc Recommends Final Dividend, Payable on 8 December 2023CVS Group plc recommends continuation of progressive dividend policy, with the payment of a final dividend of 7.5 pence per Ordinary share (2022: 7.0 pence). The ex-dividend date is 2 November 2023 and the dividend payment date is 8 December 2023.
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €19.70, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 18x in the Healthcare industry in Germany. Total returns to shareholders of 57% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €28.55 per share.
Buying Opportunity • Sep 07Now 26% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be €26.90, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 42%. For the next 3 years, revenue is forecast to grow by 6.5% per annum. Earnings is also forecast to grow by 19% per annum over the same time period.
Reported Earnings • Feb 26First half 2023 earnings released: EPS: UK£0.30 (vs UK£0.25 in 1H 2022)First half 2023 results: EPS: UK£0.30 (up from UK£0.25 in 1H 2022). Revenue: UK£296.3m (up 8.3% from 1H 2022). Net income: UK£21.1m (up 21% from 1H 2022). Profit margin: 7.1% (up from 6.4% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
공시 • Nov 23CVS Group plc Recommends Dividend, Payable on 2 December 2022CVS Group plc announced that as previously announced, and subject to shareholder approval at the AGM, the company intends to pay a dividend of 7.0 pence per ordinary share on 2 December 2022 to holders on the register as at 18 November 2022. The ex-dividend date for this timetable is 17 November 2022.
공시 • Nov 12+ 2 more updatesCVS Group plc to Report Q4, 2023 Results on Sep 21, 2023CVS Group plc announced that they will report Q4, 2023 results on Sep 21, 2023
Buying Opportunity • Nov 11Now 21% undervaluedOver the last 90 days, the stock is up 2.9%. The fair value is estimated to be €27.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 43%. For the next 3 years, revenue is forecast to grow by 5.7% per annum. Earnings is also forecast to grow by 18% per annum over the same time period.
Upcoming Dividend • Nov 10Upcoming dividend of UK£0.07 per shareEligible shareholders must have bought the stock before 17 November 2022. Payment date: 02 December 2022. Payout ratio is a comfortable 19% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (4.1%).
Recent Insider Transactions • Sep 29Independent Non-Executive Chairman recently bought €83k worth of stockOn the 22nd of September, Richard Connell bought around 5k shares on-market at roughly €18.56 per share. This transaction amounted to 2.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of €256k worth in shares.
Reported Earnings • Sep 23Full year 2022 earnings released: EPS: UK£0.36 (vs UK£0.27 in FY 2021)Full year 2022 results: EPS: UK£0.36 (up from UK£0.27 in FY 2021). Revenue: UK£554.2m (up 8.6% from FY 2021). Net income: UK£25.7m (up 33% from FY 2021). Profit margin: 4.6% (up from 3.8% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
공시 • Sep 22+ 1 more updateCVS Group plc Recommending Final DividendCVS Group plc the board is recommending a continuation of progressive dividend policy, with the payment of a final dividend of 7.0 pence per Ordinary share (2021: 6.5 pence).
공시 • Jul 02CVS Group plc (AIM:CVSG) acquired Ocvc Limited for £ 3 million.CVS Group plc (AIM:CVSG) acquired Ocvc Limited for £ 3 million on June 10, 2022. The consideration was funded from the Group's cash balances. Aubrey Powell, Jen Boorer, and Rachel Hayes of Singer Capital Markets Securities Limited acted as financial advisor to CVS Group plc. CVS Group plc (AIM:CVSG) completed the acquisition of Ocvc Limited on June 10, 2022.
공시 • May 08CVS Group plc (AIM:CVSG) acquired Anton Vets Ltd for £6 million.CVS Group plc (AIM:CVSG) acquired Anton Vets Ltd for £6 million on May 5, 2022. The consideration is being funded using the CVS Group's existing bank facilities. Aubrey Powell, Jen Boorer and Rachel Hayes of Singer Capital Markets Securities Limited acted as financial advisor to CVS Group plc. CVS Group plc (AIM:CVSG) completed the acquisition of Anton Vets Ltd on May 5, 2022.
Valuation Update With 7 Day Price Move • Feb 23Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €18.75, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 16x in the Healthcare industry in Germany. Total returns to shareholders of 260% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €34.78 per share.
Recent Insider Transactions • Dec 09Independent Non-Executive Chairman recently bought €63k worth of stockOn the 6th of December, Richard Connell bought around 3k shares on-market at roughly €25.13 per share. In the last 3 months, they made an even bigger purchase worth €110k. Richard has been a buyer over the last 12 months, purchasing a net total of €278k worth in shares.
Recent Insider Transactions • Nov 27Independent Non-Executive Chairman recently bought €110k worth of stockOn the 25th of November, Richard Connell bought around 4k shares on-market at roughly €26.17 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of €216k worth in shares.
Upcoming Dividend • Nov 11Upcoming dividend of UK£0.065 per shareEligible shareholders must have bought the stock before 18 November 2021. Payment date: 03 December 2021. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (2.4%).
Board Change • Nov 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Senior Independent Non-Executive Director Deborah Kemp was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Senior Independent Non-Executive Director Deborah Kemp was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Executive Departure • Oct 01Senior Independent Non-Executive Director Michael McCollum has left the companyOn the 23rd of September, Michael McCollum's tenure as Senior Independent Non-Executive Director ended. As of June 2021, Michael still personally held 38.68k shares (€1.1m worth at the time). Michael is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.83 years, which is considered inexperienced in the Simply Wall St Risk Model.
Reported Earnings • Sep 24Full year 2021 earnings released: EPS UK£0.27 (vs UK£0.081 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£510.1m (up 19% from FY 2020). Net income: UK£19.3m (up 239% from FY 2020). Profit margin: 3.8% (up from 1.3% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
Executive Departure • Sep 24Senior Independent Non-Executive Director Michael McCollum has left the companyOn the 23rd of September, Michael McCollum's tenure as Senior Independent Non-Executive Director ended after 8.5 years in the role. As of June 2021, Michael still personally held 38.68k shares (€1.1m worth at the time). Michael is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.83 years, which is considered inexperienced in the Simply Wall St Risk Model.
공시 • May 01CVS Group plc Provides Group Earnings Guidance for the Full Year Ending June 30, 2021CVS Group plc provided earnings guidance for the full year ending June 30, 2021. This, coupled with the continued delivery of the vaccination programme and further easing of lockdown restrictions, means the Board is increasingly confident that this strong performance will continue for the remaining months of this financial year. Consequently, the Group now expects full year revenue to be ahead of current management expectations.
Recent Insider Transactions • Mar 31Non-Executive Director recently bought €66k worth of stockOn the 29th of March, Richard Gray bought around 3k shares on-market at roughly €21.93 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Mar 26First half 2021 earnings released: EPS UK£0.16 (vs UK£0.079 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£245.6m (up 9.4% from 1H 2020). Net income: UK£11.3m (up 102% from 1H 2020). Profit margin: 4.6% (up from 2.5% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Mar 11New 90-day high: €20.62The company is up 37% from its price of €15.06 on 10 December 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €25.14 per share.
공시 • Jan 28+ 2 more updatesCVS Group plc, Annual General Meeting, Nov 24, 2021CVS Group plc, Annual General Meeting, Nov 24, 2021.
Is New 90 Day High Low • Jan 22New 90-day high: €17.06The company is up 25% from its price of €13.67 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.26 per share.
Is New 90 Day High Low • Jan 05New 90-day high: €16.96The company is up 29% from its price of €13.18 on 07 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.75 per share.
Is New 90 Day High Low • Dec 18New 90-day high: €16.49The company is up 32% from its price of €12.53 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.87 per share.
공시 • Nov 26CVS Group plc Announces Appointment of Enrico Tizzano as its First Chief Technology OfficerCVS Group plc announced that the Group has strengthened its management team with the appointment of Enrico Tizzano as its first Chief Technology Officer. Enrico will support the effective use of technology and data in delivery of the Group's strategic objectives and has a wealth of experience from previous CTO roles in large, consumer-facing organizations.
Is New 90 Day High Low • Nov 05New 90-day high: €14.38The company is up 14% from its price of €12.57 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.11 per share.
Is New 90 Day High Low • Sep 28New 90-day high: €13.89The company is up 26% from its price of €11.06 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.81 per share.
Reported Earnings • Sep 26Full year earnings released - EPS €0.081Over the last 12 months the company has reported total profits of UK£5.70m, down 31% from the prior year. Total revenue was UK£427.8m over the last 12 months, up 5.2% from the prior year. Profit margins were 1.3%, which is in line with last year.
공시 • Sep 24CVS Group plc Not Propose Final DividendThe directors of CVS Group plc have proposed a final dividend of £nil (2019: 5.5 pence) per share, giving a total of £nil (2019: £3.9 million). During the year a dividend of 5.5 pence per share amounting to £3.9 million was paid (2019: £3.5 million).
